Drug Discovery
ByCan Novo Nordisk Defend Its Obesity Crown as Competition With Eli Lilly Intensifies in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo Nordisk is set…
Will Eli Lilly’s 2025 Earnings Prove That AI Is the Hidden Engine Behind Its Next Phase of Scale?
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is set to report…
Will Sanofi’s 2025 Earnings Cement Dupixent’s Leadership—and Its Next Growth Wave in Atopic Dermatitis?
Late January 2026 | Full-Year 2025 Earnings Preview | Immunology & Dermatology Focus Sanofi is set to report…
Can AbbVie’s 2025 Earnings Prove Its Post-Humira Portfolio Is Built for the Next Decade?
Late January 2026 | Full-Year 2025 Earnings Preview | Biopharma Growth Strategy AbbVie is set to report its…
Are AI Healthcare Tools Raising Ethical and Access Concerns?
January 26, 2026 | AI in Healthcare | Ethics, Equity & Policy Recent commentary in leading medical and…
Is “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?
January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the AI platform often…
